- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 103,640 | 23.09.24 14:34:43 | +0,080 | +0,08% | 103,760 | 103,820 | 103,360 | 103,560 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 1.023,500 | 23.09.24 09:43:53 | +0,500 | +0,05% | 1.029,500 | 1.035,500 | 1.020,000 | 1.023,000 |
